World's Best Scientists 2026 revealed!
Junji Furuse

Junji Furuse

D-Index & Metrics

Medicine

D-Index
80
Citations
30522
World Ranking
16939
National Ranking
534

Junji Furuse publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Junji Furuse sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 635 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Junji Furuse D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Junji Furuse sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Junji Furuse is affiliated with Kyorin University in Japan and has contributed extensively to the field of Medicine, focusing primarily on Oncology. Their work spans subfields such as Surgery, Pulmonary and Respiratory Medicine, Hepatology, and Epidemiology.

Their research concentrates on several main topics including Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Hepatocellular Carcinoma Treatment and Prognosis, Neuroendocrine Tumor Research Advances, Cancer Genomics and Diagnostics, Gallbladder and Bile Duct Disorders, and Colorectal Cancer Treatments and Studies.

Junji Furuse has published numerous papers, with notable recent works being:

  • "Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma" (2022, NEJM Evidence)
  • "Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial" (2023, The Lancet)
  • "Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma" (2023, New England Journal of Medicine)
  • "Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma" (2020, Journal of Hepatology)
  • "Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA." (2022, Journal of Clinical Oncology)

The scientist often collaborates with other researchers, including frequent co-authors such as Masafumi Ikeda, Makoto Ueno, Takuji Okusaka, Masato Ozaka, and Chigusa Morizane.

Their work is regularly published in high-impact journals, with common venues for their publications being:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Hepato-Biliary-Pancreatic Sciences
  • Japanese Journal of Clinical Oncology
  • Pancreatology

Best Publications

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

    Alan P. Venook;Christos Papandreou;Junji Furuse;Laura Ladrón de Guevara

  • Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

    T Okusaka;K Nakachi;A Fukutomi;N Mizuno

  • Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa

  • Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

    Masatoshi Kudo;Kazuho Imanaka;Nobuyuki Chida;Kohei Nakachi

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

    Masatoshi Kudo;Kazuomi Ueshima;Masafumi Ikeda;Takuji Torimura

  • Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

    Hedy L Kindler;Tatsuya Ioka;Dirk J Richel;Jaafar Bennouna

  • Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

    Juan W Valle;J Furuse;M Jitlal;S Beare

  • Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

    Fuyuhiko Motoi;Tomoo Kosuge;Hideki Ueno;Hiroki Yamaue

  • Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

    Jorge A. Marrero;Masatoshi Kudo;Alan P. Venook;Sheng Long Ye

  • Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.

    Yoshiaki Nakamura;Hiroya Taniguchi;Masafumi Ikeda;Hideaki Bando

  • Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.

    Yu Sawada;Toshiaki Yoshikawa;Daisuke Nobuoka;Hirofumi Shirakawa

  • Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Bruno Sangro;Ignacio Melero;Samir Wadhawan;Richard S Finn

  • Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition

    Masaru Miyazaki;Hideyuki Yoshitomi;Shuichi Miyakawa;Katsuhiko Uesaka

  • Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

    Makoto Ueno;Masafumi Ikeda;Chigusa Morizane;Satoshi Kobayashi

  • GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

    R. Lencioni;M. Kudo;S. L. Ye;J. P. Bronowicki

  • Chemotherapy for hepatocellular carcinoma: current status and future perspectives.

    Masafumi Ikeda;Chigusa Morizane;Makoto Ueno;Takuji Okusaka

  • Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment

    Satoshi Kondo;Tadahiro Takada;Masaru Miyazaki;Shuichi Miyakawa

  • Phase II Study of Radiotherapy Employing Proton Beam for Hepatocellular Carcinoma

    Mitsuhiko Kawashima;Junji Furuse;Teiji Nishio;Masaru Konishi

Frequent Co-Authors

Takuji Okusaka
Takuji Okusaka National Cancer Centre
Masatoshi Kudo
Masatoshi Kudo Kindai University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Shoji Nakamori
Shoji Nakamori Osaka University
Juan W. Valle
Juan W. Valle University of Manchester
Masaru Miyazaki
Masaru Miyazaki International University of Health and Welfare
Tadatoshi Takayama
Tadatoshi Takayama Nihon University
Shuichi Kaneko
Shuichi Kaneko Kanazawa University
Jun-ichi Sawada
Jun-ichi Sawada University of Shizuoka

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in studying Medicine in the USA, several online degrees and certifications can broaden your career options in healthcare. One popular area is online nutrition degrees, which prepare graduates to work in wellness, dietetics, and public health. This pathway is ideal for those who wish to help others improve their health through dietary and lifestyle changes.

Management roles in healthcare are also in high demand. Completing a cahme-accredited Master of Healthcare Administration (MHA) program online can help launch a career in hospital leadership, health systems management, or clinic administration.

For current registered nurses, flexible options like rn to bsn with no clinicals programs offer a way to advance qualifications without the need for in-person clinical components. This makes it easier to gain new skills while continuing to work.

Those aiming for advanced practice or executive roles should explore the shortest msn to dnp program offerings. These online programs help nurses quickly earn terminal degrees and qualify for top positions in practice, education, or administration.

Best Scientists Citing Junji Furuse

Trending Scientists